Brand Name : Cometriq
Composition : Cabozantinib
Strength availability : 80mg
Manufactured by : Exelixis.Inc
Form : capsules
Pack : 30 tablets
for MORE INFORMATION !!!
Cometriq 80mg which is a type of targeted therapy drug used to recover from medullary thyroid cancer and kidney cancer that has spread.
Its label contains a black box warning of gastrointestinal perforations, fistulas, and haemorrhage.
Cometriq 80mg is a prescription drug which is used under the supervision of doctors
Cometriq 80mg is used for the treatment of metastatic medullary thyroid cancer and for the treatment of patients having advanced renal cell carcinoma (RCC) who have getting before anti-angiogenic therapy.
Avoid substitute Cometriq tablets with Cabozantinib capsules.
The prescribed dose of Cometriq is 60 mg.
Administration Cometriq is without food.
Advise the patients not to eat for at least 2 hours before and 1 hour after taking cometriq. Follow the treatment until patient no longer experiences clinical benefit or experiences unacceptable toxicity.
Swallow Cometriq tablets whole. Do not crush Cometriq tablets.
Cabozantinib is also called as tyrosine kinase inhibitor (targeted therapy drug). It works by prohibiting the signals inside cancer cells which made them grow and multiple. This may help to block or reduced the growth of the cancer. It can also prohibit new blood vessels growing in the cancer. Cancer cells require to make new blood vessels, so they can develop and spread.
high plasma concentration is observed in 2-5 hours
bounding of Cometriq has human plasma protein ≥ 99.7%
Mainly metabolized by CYP3A4 and minorly by CYP2C9
eliminated mostly through feces 54 % and in urine 27% and half-life is 55 hours
Monitor the patients for symptoms of perforations and fistulas, contain abscess. stop Cometriq 80mg in patients who experience a perforation or a fistula.
Do not administer Cometriq 80mg to patients with a present history of haemorrhage or haemoptysis.
Discontinue the Cometriq 80mg in patients who develop an acute myocardial infarction, cerebral infarction, or any other clinically significant arterial thromboembolic complication.
Discontinue the Cometriq 80mg for patient if have severe hypertension that cannot be controlled with anti-hypertensive therapy.
Inform pregnant women about possible harm to a foetus. Inform females of reproductive probable to use efficient contraception during treatment with Cometriq 80mg and for 4 months after the last dose.
Cometriq 80mg concomitant use with strong CYP3A4 inhibitor will increase the single dose plasma Cabozantinib exposure by 38%.
Cometriq 80mg concomitant use with strong CYP3A4 inducers will decreased the single dose plasma Cabozantinib exposure by 77%
Cometriq 80mg Combination with MRP2 inhibitors may increase the exposure to Cabozantinib
Cometriq 80mg is contraindicated patients having hypersensitivity reaction to the active substance or its excipients.
If the patient vomits after taking a dose of Cometriq 80mg or missed to take a dose, then should not to take an extra dose, but to take the next dose at the regular time, skip the missed dose. Do not take the missed dose within 12 hours of next dose.
Store the drug at 20℃ to 25℃
Keep away from the children resistances
• Thrombotic events
• Hypertension and hypertensive crisis
• Palmar-plantar erythrodysesthesia
• Reversible posterior leukoencephalopathy syndrome
• GI perforations and fistulas